# Zelquistinel in the Treatment of Major Depressive Disorder

> **NCT03586427** · PHASE2 · COMPLETED · sponsor: **Syndeio Biosciences, Inc** · enrollment: 251 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** AGN-241751
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03586427
- **Lead sponsor:** Syndeio Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-08-21
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586427, "Zelquistinel in the Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03586427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*